These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38483988)

  • 1. Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7.
    Boretto M; Geurts MH; Gandhi S; Ma Z; Staliarova N; Celotti M; Lim S; He GW; Millen R; Driehuis E; Begthel H; Smabers L; Roodhart J; van Es J; Wu W; Clevers H
    Proc Natl Acad Sci U S A; 2024 Mar; 121(12):e2309902121. PubMed ID: 38483988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of FBXW7 in Gynecologic Malignancies.
    Di Fiore R; Suleiman S; Drago-Ferrante R; Subbannayya Y; Suleiman S; Vasileva-Slaveva M; Yordanov A; Pentimalli F; Giordano A; Calleja-Agius J
    Cells; 2023 May; 12(10):. PubMed ID: 37408248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular insights and clinical implications for the tumor suppressor role of SCF
    Qi Y; Rezaeian AH; Wang J; Huang D; Chen H; Inuzuka H; Wei W
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189140. PubMed ID: 38909632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination.
    Zhu H; Wang X; Zhou X; Lu S; Gu G; Liu C
    Lab Invest; 2022 Nov; 102(11):1203-1213. PubMed ID: 35840806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent insight into the role of FBXW7 as a tumor suppressor.
    Yumimoto K; Nakayama KI
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):1-15. PubMed ID: 32113998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ubiquitin ligase FBXW7 targets the centriolar assembly protein HsSAS-6 for degradation and thereby regulates centriole duplication.
    Badarudeen B; Gupta R; Nair SV; Chandrasekharan A; Manna TK
    J Biol Chem; 2020 Apr; 295(14):4428-4437. PubMed ID: 32086376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F-box and WD repeat domain-containing-7 (Fbxw7) protein targets endoplasmic reticulum-anchored osteogenic and chondrogenic transcriptional factors for degradation.
    Yumimoto K; Matsumoto M; Onoyama I; Imaizumi K; Nakayama KI
    J Biol Chem; 2013 Oct; 288(40):28488-502. PubMed ID: 23955342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HTLV-I oncoprotein Tax inactivates the tumor suppressor FBXW7.
    Bellon M; Yeh C-h; Bai XT; Nicot C
    J Virol; 2024 Jul; 98(7):e0040524. PubMed ID: 38874362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
    Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E3-ubiquitin ligase, FBXW7 regulates mitotic progression by targeting BubR1 for ubiquitin-mediated degradation.
    Nair VM; Sabu AS; Hussain A; Kombarakkaran DP; Lakshmi RB; Manna TK
    Cell Mol Life Sci; 2023 Nov; 80(12):374. PubMed ID: 38008853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitylation of unphosphorylated c-myc by novel E3 ligase SCF
    Bajpai S; Jin HR; Mucha B; Diehl JA
    Cancer Biol Ther; 2022 Dec; 23(1):348-357. PubMed ID: 35438057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
    Hidayat M; Mitsuishi Y; Takahashi F; Tajima K; Yae T; Miyahara K; Hayakawa D; Winardi W; Ihara H; Koinuma Y; Wirawan A; Nurwidya F; Kato M; Kobayashi I; Sasaki S; Takamochi K; Hayashi T; Suehara Y; Moriyama M; Moriyama H; Habu S; Takahashi K
    Bosn J Basic Med Sci; 2019 Nov; 19(4):355-367. PubMed ID: 31202256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FBXW7/hCDC4 is a general tumor suppressor in human cancer.
    Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
    Cancer Res; 2007 Oct; 67(19):9006-12. PubMed ID: 17909001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FBXW7: a critical tumor suppressor of human cancers.
    Yeh CH; Bellon M; Nicot C
    Mol Cancer; 2018 Aug; 17(1):115. PubMed ID: 30086763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Discovery of FBXW7-Binding Phosphodegrons Highlights Mitogen-Activated Protein Kinases as Important Regulators of Intracellular Protein Levels.
    Singh N; Zeke A; Reményi A
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early growth response-1 is a new substrate of the GSK3β-FBXW7 axis.
    Yin L; Zhang J; Sun Y
    Neoplasia; 2022 Dec; 34():100839. PubMed ID: 36240645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2.
    Jiménez-Izquierdo R; Morrugares R; Suanes-Cobos L; Correa-Sáez A; Garrido-Rodríguez M; Cerero-Tejero L; Khan OM; de la Luna S; Sancho R; Calzado MA
    Cell Death Dis; 2023 Mar; 14(3):202. PubMed ID: 36934104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Interactions of EBP1 Isoforms with FBXW7 Elicits Different Functions in Cancer.
    Wang Y; Zhang P; Wang Y; Zhan P; Liu C; Mao JH; Wei G
    Cancer Res; 2017 Apr; 77(8):1983-1996. PubMed ID: 28209614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.
    Babaei-Jadidi R; Li N; Saadeddin A; Spencer-Dene B; Jandke A; Muhammad B; Ibrahim EE; Muraleedharan R; Abuzinadah M; Davis H; Lewis A; Watson S; Behrens A; Tomlinson I; Nateri AS
    J Exp Med; 2011 Feb; 208(2):295-312. PubMed ID: 21282377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRL2
    Motomura S; Yumimoto K; Tomonaga T; Nakayama KI
    Oncogene; 2024 Jun; 43(25):1917-1929. PubMed ID: 38698266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.